New York: Recently approved antiviral medications for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80 percent, researchers have estimated.

The finding raises the possibility of greatly reducing, and even eliminating, hepatitis C if enhanced screening and treatment efforts target high-risk populations -- injection-drug users.